Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/13495
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.otherUCH. Departamento de Medicina y Cirugía Animal-
dc.contributor.otherProducción Científica UCH 2021-
dc.creatorPeláez Gorrea, Pau-
dc.creatorDamiá Giménez, Elena-
dc.creatorTorres Torrillas, Marta-
dc.creatorChicharro Alcántara, Deborah-
dc.creatorCuervo Serrato, Belén-
dc.creatorMiguel Pastor, Laura-
dc.creatorRomero Martínez, Ayla del-
dc.creatorCarrillo Poveda, José María.-
dc.creatorSopena Juncosa, Joaquín Jesús.-
dc.creatorRubio Zaragoza, Mónica.-
dc.date2021-
dc.date.accessioned2022-03-12T05:00:22Z-
dc.date.available2022-03-12T05:00:22Z-
dc.date.issued2021-11-19-
dc.identifier.citationPeláez, P., Damiá, E., Torres-Torrillas, M., Chicharro, D., Cuervo, B., Miguel, L., Del Romero, A., Carrillo, J.M., Sopena, J.J. & Rubio, M. (2021). Cell and cell free therapies in osteoarthritis. Biomedicines, vol. 9, i. 11 (19 nov.), art. 1726. DOI: https://doi.org/10.3390/biomedicines9111726-
dc.identifier.issn2227-9059 (Electrónico)-
dc.identifier.urihttp://hdl.handle.net/10637/13495-
dc.descriptionEste artículo se encuentra disponible en la siguiente URL: https://www.mdpi.com/2227-9059/9/11/1726-
dc.descriptionEste artículo pertenece al número especial "Adipose-Derived Mesenchymal Stem Cells, Cell-Based Therapies, and Biomaterials as New Regenerative Strategies".-
dc.description.abstractOsteoarthritis (OA) is the most common articular disease in adults and has a current prevalence of 12% in the population over 65 years old. This chronic disease causes damage to articular cartilage and synovial joints, causing pain and leading to a negative impact on patients’ function, decreasing quality of life. There are many limitations regarding OA conventional therapies—pharmacological therapy can cause gastrointestinal, renal, and cardiac adverse effects, and some of them could even be a threat to life. On the other hand, surgical options, such as microfracture, have been used for the last 20 years, but hyaline cartilage has a limited regeneration capacity. In recent years, the interest in new therapies, such as cell-based and cell-free therapies, has been considerably increasing. The purpose of this review is to describe and compare bioregenerative therapies’ efficacy for OA, with particular emphasis on the use of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP). In OA, these therapies might be an alternative and less invasive treatment than surgery, and a more effective option than conventional therapies.-
dc.formatapplication/pdf-
dc.language.isoen-
dc.language.isoes-
dc.publisherMDPI-
dc.relationEste artículo de investigación ha sido financiado por la Cátedra de Fundación García Cugat de la UCH y por la Universidad CEU Cardenal Herrera.-
dc.relationUCH. Financiación Universidad-
dc.relation.ispartofBiomedicines, vol. 9, n. 11 (19 nov. 2021)-
dc.rightshttp://creativecommons.org/licenses/by/4.0/deed.es-
dc.subjectOsteoartritis - Tratamiento.-
dc.subjectCrecimiento - Factores - Uso terapéutico.-
dc.subjectPlasma sanguíneo - Uso terapéutico.-
dc.subjectStem cells - Therapeutic use.-
dc.subjectGrowth factors - Therapeutic use.-
dc.subjectOsteoarthritis - Treatment.-
dc.subjectCélulas madre - Uso terapéutico.-
dc.subjectBlood plasma - Therapeutic use.-
dc.titleCell and cell free therapies in osteoarthritis-
dc.typeArtículo-
dc.identifier.doihttps://doi.org/10.3390/biomedicines9111726-
dc.centroUniversidad Cardenal Herrera-CEU-
Aparece en las colecciones: Dpto. Medicina y Cirugía Animal




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.